ArticleJournal of health economics and outcomes research2025

Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.

Niodita Gupta-Werner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.